Search PubMed⌕ Search

SEARCH · Search PubMed

Results for “PHARMACOLOGY”

Search indexed PubMed citations on genomics, clinical trials, systematic reviews and public health. Explore titles, authors and supplied subject terms, then open the PubMed record.

Quote a phrase for an exact phrase match. Source license links do not imply unrestricted reuse.

At least 919 records · Page 51Linked to original sources

Native gamma-aminobutyric acid type A receptors from rat hippocampus, containing both alpha 1 and alpha 5 subunits, exhibit a single benzodiazepine binding site with alpha 5 pharmacological properties.

Evidences indicate the existence of two homologous and/or heterologous alpha subunits coassembled in a single gamma-aminobutyric acid type A (GABA(A)) receptor. However, it is unknown whether both or only one of the coassembled alpha subunits display benzodiazepine binding sites. Thus, we have investigated the association between alpha1 and alpha5 subunits and the pharmacological properties of these GABA(A) receptors from rat hippocampus. The association between alpha1 and alpha5 subunits was demonstrated by immunoblot of the anti-alpha1 or -alpha5 immunoaffinity-purified receptors and by double immunopurification by anti-alpha1 and -alpha5 columns in series. The benzodiazepine binding properties of the immunoprecipitated receptors indicated the existence of pharmacologically active and inactive alpha subunits. The anti-alpha5 immunoprecipitated receptors displayed exclusively low-affinity binding sites for both Cl218,872 (K(i) = 0.81 +/- 0.15 microM) and zolpidem (K(i) = 5.0 +/- 3.0 microM), in spite of the association between alpha1 and alpha5 subunits. The anti-alpha1 immunoprecipitated receptors displayed both high- and low-affinity binding sites for both ligands (K(i)s = 47.5 +/- 5.2 nM and 0.7 +/- 0.06 microM for Cl218,872 and 25.0 +/- 7.0 nM, 415 +/- 200 nM and 9. 3 +/- 3.0 microM for zolpidem). Therefore, the alpha5 subunit, when coassembled with alpha1 subunit, should be pharmacologically predominant. This hypothesis was probed by immunoprecipitation of the photoaffinity-labeled receptors and by anti-alpha1 and -alpha5 double immunopurified receptors. The alpha1-alpha5 double immunopurified receptors displayed a single low-affinity binding site (K(i) = 908 +/- 105 nM) for Cl218,872, undetectable [(3)H]zolpidem binding activity, and similar [(3)H]flumazenil and [(3)H]L-655,708 binding activity (0.10 +/- 0.01 and 0.09 +/- 0.02 pmol/20 microliters of anti-alpha5 immunobeads, respectively). Thus, the native GABA(A) receptors containing alpha1 and alpha5 subunits have only one alpha subunit pharmacologically active displaying alpha5 binding properties.

Animals↗

Comparative pharmacological and functional analysis of the human dopamine D4.2 and D4.10 receptor variants.

The human dopamine D4 receptor is a D2-like receptor which is a target for most common neuroleptics. Previous investigations have shown that this receptor displays a large polymorphic variation in the third intracellular loop involving a variable number of direct imperfect tandem repeats (VNTR) of 16 amino acids. The shortest and longest repeat variants reported to date contain two and 10 repeat units (D4.2 and D4.10). No major pharmacological differences have been reported for the most common variants of this receptor (D4.2, D4.4 and D4.7), although the D4.7 was reported by us to display a slightly lower potency for dopamine in functional assays. Direct pharmacological and functional comparison of the longest and shortest variants in this study suggest no major discrepancies in pharmacological or functional profile between both receptors. Both receptors display, on average, a 15-fold and 90-fold lower potency for epinephrine and norepinephrine, respectively, compared with dopamine. We observed small increases in functional potency and affinity for dopamine and quinpirole at the D4.10 receptor variant compared with the D4.2 receptor. Our data indicate that there is no direct relationship between the length of the polymorphism and changes in pharmacology or functional activity. These findings are a suitable caution against the arbitrary pooling of D4 receptor VNTR genotypes in genetic studies, based on length.

Amino Acid Sequence↗

Native N-methyl-D-aspartate receptors containing NR2A and NR2B subunits have pharmacologically distinct competitive antagonist binding sites.

The pharmacological properties of native N-methyl-D-aspartate (NMDA) receptors were determined in rat brain sections with quantitative autoradiography of [(3)H](E)-2-amino-4-propyl-5-phosphono-3-pentenoic acid (CGP39653) binding. With five competitive antagonists as displacers, two subpopulations of binding sites were observed in the horizontal plane of section examined. These two populations corresponded anatomically to NR2A and NR2B subunits. Quantitative analysis of NR2A-like and NR2B-like binding sites was enabled by examining the cerebellar granule cell layer, which expresses NR2A and NR2C subunits, and the medial striatum, which predominately expresses NR2B subunits. The antagonists (R)-(E)-4-(3-phosphonoprop-2-enyl)piperazine-2-carboxylic acid and (R)-2-amino-5-phosphonopentanoate (D-AP5) displayed similar affinities at cerebellar NMDA receptors and medial striatal NMDA receptors. In contrast, the NMDA receptor antagonists (+/-)-6-(1H-Tetrazol-5-ylmethyl)decahydroisoquinoline- 3-carboxylic acid, (S)-alpha-amino-5-(phosphonomethyl)[1,1'-biphenyl]-3-propanoic acid, and (+/-)-cis-4-(4-phenylbenzoyl) piperazine-2,3-dicarboxylic acid displayed varied, higher affinities at medial striatal NMDA receptors than at cerebellar NMDA receptors. For the five antagonists, there was a strong correlation (r = 0.9) between the cerebellar K(i)/medial striatum K(i) ratio and the NR2A K(i)/NR2B K(i) ratio for recombinant receptors. Thus, [(3)H]CGP39653 labels two pharmacologically distinct populations of NMDA receptors that have pharmacological and anatomical properties consistent with NR2A and NR2B subunits. Because native NR2A- and NR2B-containing receptors are pharmacologically distinct, it should be possible to develop NR2A- and NR2B-selective glutamate site antagonists.

2-Amino-5-phosphonovalerate↗

Cloning of rat histamine H(3) receptor reveals distinct species pharmacological profiles.

The recent cloning and characterization of the human histamine H(3) receptor cDNA marked a significant step toward a greater understanding of the role of this receptor in the central nervous system. We now report the cloning of the rat histamine H(3) receptor cDNA and demonstrate distinct pharmacological species differences. The rat cDNA clone encodes a putative 445-amino acid protein with 93% identity to the human H(3) receptor. Northern blot analysis revealed a major single entity of 2.7-kb in length expressed only in brain. Transfection of the rat receptor cDNA into SK-N-MC cells conferred an ability to inhibit forskolin-stimulated cAMP formation in response to histamine and other H(3) agonists. N-[(3)H]methylhistamine saturably bound to transfected cells with high affinity (K(d) = 0.8 nM). All agonists tested had low or subnanomolar K(i) values similar to that for the human recombinant receptor. The antagonists thioperamide and clobenpropit also bound with high affinity (K(i) = 4 and 0.4 nM, respectively). This is in contrast to the antagonist profile obtained for the human recombinant receptor that showed K(i) values of 58 and 0.6 nM for thioperamide and clobenpropit, respectively. These data suggest that the low affinity of thioperamide for the human H(3) receptor represents a species difference in pharmacology and not a unique pharmacological subtype. It also was found that chloroproxyfan behaved as a full agonist at the rat recombinant receptor. These findings highlight the significance of validating the pharmacology of experimental compounds at both the rat and human H(3) receptors.

Adenylyl Cyclase Inhibitors↗

Intraoperative pharmacological erection as an aid to pediatric hypospadias repair.

PURPOSE: The intraoperative evaluation of erection is a major advance in hypospadias surgery. We determined the advantages of erections induced pharmacologically over those induced by intracorporeal saline injection for evaluating chordee during hypospadias surgery. MATERIALS AND METHODS: During the repair of hypospadias or chordee without hypospadias 56 boys 6 months to 13 years old underwent pharmacological erection induced by 14 microg. alprostadil administered intracavernously. Phenylephrine (40 microg. ) was given for detumescence. We monitored the adequacy of erection and detumescence, changes in blood pressure and pulse, and in 3 cases intracorporeal pressure. Intraoperative artificial erection was also induced in 30 patients. RESULTS: Erection occurred within 1 minute of injection. It was judged to be excellent in 47 cases and adequate in 6, while it failed in 3 probably due to injection outside of the corpora. Erection involved the whole penis, in contrast to artificial erection when tourniquet placement altered the erection and left the penile base flaccid. The degree of chordee remained stable during evaluation compared to artificial erection when curvature varied with the force of the saline injection. Erection persisted during chordee repair as long as the corpora were not opened. Detumescence occurred within seconds in all cases in which phenylephrine was given. There were no cases of priapism, and systemic blood pressure and pulse did not change. Intracorporeal pressure during pharmacological erection was 47 to 70 mm. Hg, whereas during artificial erection pressure was 50 to 250 mm. Hg depending on how much saline was injected and how rapidly fluid drained through the tourniquet. Chordee was induced by over injection. CONCLUSIONS: Pharmacological erection in hypospadias repair is effective and reliable with no significant complications. It is especially valuable in severe hypospadias and in patients with a large suprapubic fat pad. Artificial erection with saline injection should be performed with only moderate force since over filling is unphysiological and may falsely induce chordee.

Adolescent↗

[Cryopreserved Isolated Tissues in Pharmacological Research]

Studies on the mechanism of action of drugs are usually performed on freshly obtained tissues from various animal species. Despite its relevance to human pharmacology the use of human isolated tissues in pharmacological experiments is still very much the exception rather than the rule. The major reason for this is the irregular and unpredictable availability of human tissues. This article considers the usefulness of cryopreservation to store vascular and nonvascular mammalian tissues for subsequent pharmacological studies. Despite certain problems, such as diminished contractile force, the technique does offer clear potential for ensuring the supply of both vascular and nonvascular tissues from animal and man for pharmacological studies.

Journal Article↗

Integration of molecular biological techniques and behavioural pharmacology.

The rapidly advancing technology in the area of molecular neuroscience has greatly expanded the tools available to behavioural pharmacologists for investigating the molecular bases underlying the interrelation of pharmacological agents and behaviour. Strategies such as gene targeted knockout mutations, expression of an exogenous transgene, as well as the disruption of the cellular expression of genes with antisense oligonucleotides, are being successfully used to study normal and impaired behavioural function. Advantages of these genetic methods include the ability to manipulate systems for which selective pharmacological ligands do not exist, and the opportunity to study the interaction between genotype and environment without having to rely on spontaneously occurring mutants or selective breeding programmes. By targeting particular genes, questions can be asked about how genes control neuronal function and how manipulations of these genes affect behaviour. In particular, these strategies have been applied to studies of the molecular bases for disrupted behaviours, the behavioural actions of psychoactive drugs, and models of neuropsychiatric and neuropathological disorders. These emerging molecular biological techniques complement traditional pharmacological analysis to provide a very powerful approach with which to study the molecular correlates of behavioural pharmacology.

Journal Article↗

[Angiotensin converting enzyme inhibitors (ACEIs) and angiotensin II receptor antagonists. Pharmacologic features].

The development of pharmacological agents that block the renin-angiotensin system (RAS) specifically have helped to define all the components of the system and their contribution to blood-pressure control and to the pathogenesis of hypertension, congestive heart failure and chronic renal failure. The angiotensin converting-enzyme inhibitors (ACEi) are among all available drugs that interfere with the RAS, the most efficient, so far, in the treatment of several cardiovascular diseases, with comfortable posologic schemes and an acceptable safety profile. The most important difference between them are more related to pharmacokinetic profile rather than to pharmacodynamic characteristics. With the use of ACEi the interference with other neurohumoral systems is unavoidable and the controversy has been pharmacologically and clinically installed. With the advent of oral selective AT1 angiotensin II receptor blockers (ARB) the pharmacological interference became eventually much more selective. Their antihypertensive efficacy is identical and their tolerability is better than that showed by ACEi. The ARBs differ mainly in their pharmacokinetics and in their binding capacity to the AT1 angiotensin receptor. The results of several ongoing clinical trials will show if the ARBs as ACEi will be capable to protect target-organs and to promote a significant reduction in cardiovascular morbility and mortality. In parallel there is an intense experimental and clinical research with other groups of drugs which also markedly interfere with RAS: renin inhibitors, chymase inhibitors and simultaneous inhibitors of vasopeptidases (ACE, endothelin converting-enzyme, neutral endopeptidase). From the pharmacological point of view, it is now possible to block effectively RAS with some relevant clinical results that will be certainly widen in the near future.

Angiotensin Receptor Antagonists↗

Incremental prognostic value of RNA ejection fraction measurements during pharmacologic stress testing: a comparison with clinical and perfusion variables.

UNLABELLED: This investigation examined the prognostic power of first-pass radionuclide angiocardiography (RNA) ejection fraction compared with clinical information and myocardial perfusion imaging in patients undergoing pharmacologic stress testing. The value of RNA and myocardial perfusion imaging in predicting death or nonfatal myocardial infarction (MI) is well established. However, limited information exists on the usefulness of combined myocardial perfusion imaging and RNA to predict prognosis, especially in patients undergoing pharmacologic stress testing. METHODS: We identified 240 patients who underwent pharmacologic stress testing with myocardial perfusion imaging and combined RNA. The patients were followed for a mean of 1.4 y. Cox proportional hazards models were used to assess the value in predicting death and MI. Multivariable models were generated to assess the independent incremental predictive value of clinical and nuclear imaging variables. Kaplan-Meier survival and event-free survival estimates were examined in patients with low (< or = 45%) versus high (>45%) ejection fractions. RESULTS: Clinical information, myocardial perfusion imaging, and RNA ejection fraction were significant predictors of the death/MI composite outcome (chi(2) = 7.4, 14.0, and 21.8, respectively). The addition of myocardial perfusion imaging to the clinical information provided incremental prognostic information (chi(2) = 15.2). The addition of RNA ejection fraction provided further predictive information (chi(2) = 22.5). However, when RNA ejection fraction was first added to the clinical information, myocardial perfusion imaging had no incremental prognostic value. CONCLUSION: For hard cardiac events, RNA ejection fraction provides prognostic information besides that provided by clinical and myocardial perfusion imaging. In patients who cannot exercise and are undergoing noninvasive evaluation with pharmacologic stress testing and myocardial perfusion imaging, ejection fraction should be measured simultaneously for risk assessment optimization.

Adenosine↗

[Non-pharmacological treatment of hypertension in practice of primary care physicians].

The role of non-pharmacological methods in prevention and treatment of hypertension is well documented. Weight in patients with overweight and obesity, sodium intake restriction and alcohol drinking limitation are especially effective in arterial pressure reduction. The aim of this questionnaire study was to evaluate the knowledge and skills in that field of physicians working in primary health care. The study was done with 91 physicians working in Warsaw District. All of them declared that they give instructions about life style to their patients with hypertension. In majority it was oral consultation (36 persons, 39%) or oral consultation with distribution of booklets or brochures (48 persons, 52%). Six physicians (7%) sent patients to specialist. Pharmacological treatment was started most often from the systolic pressure 160 mmHg (59 persons, 64%) and diastolic pressure 100 mmHg (39 persons, 42%). Non-pharmacological advice was given most often at systolic pressure above 140 mmHg (44 persons, 48%) and diastolic pressure above 90 mmHg (67 persons, 73%). Salt intake reduction was advised always or usually by 82 physicians (90%), alcohol drinking reduction by 77 persons (85%) and tobacco smoking cessation by 86 persons (95%). Regular physical activity was advised always or usually by 75 persons (82%). Evaluation of nutrition was done predominantly by asking a few not-formal questions (62 persons, 67%). Only 1 physical used daily diary of nutrition. Similarly in evaluation of physical activity 62 persons (67%) used only not-formal questions. It is worthily to note that 36 persons (40%) considered that they need more skills to give advices of healthy life style, 49 persons (53%) did not enough time to do that and 30 persons (33%) thought that it is hard to give advices they can't keep themselves. All questionnaire physicians declared to use non-pharmacological treatment in patients with hypertension. Quite good knowledge of essential recommendations in that field was stated. The results of this questionnaire indicate that many physicians estimate their knowledge and skills as low in that sphere.

Adult↗

Pharmacologic mitogen-activated protein/extracellular signal-regulated kinase kinase/mitogen-activated protein kinase inhibitors interact synergistically with STI571 to induce apoptosis in Bcr/Abl-expressing human leukemia cells.

Interactions between the kinase inhibitor STI571 and pharmacological antagonists of the mitogen-activated protein/extracellular signal-regulated kinase kinase (MEK)/mitogen-activated protein kinase (MAPK) cascade have been examined in human myeloid leukemia cells (K562 and LAMA 84) that express the Bcr-Abl kinase. Exposure of K562 cells to concentrations of STI571 that minimally induced apoptosis (e.g., approximately 200 nM) resulted in early suppression (i.e., at 6 h) of p42/44 MAPK phosphorylation followed at later intervals (i.e., > or =24 h) by a marked increase in p42/44 MAPK phosphorylation/activation. Coadministration of a nontoxic concentration of the MEK1/2 inhibitor PD184352 (5 microM) prevented STI571-mediated activation of p42/44 MAPK. Cells exposed to STI571 in combination with PD184352 for 48 h demonstrated a very dramatic increase in mitochondrial dysfunction (e.g., loss of DeltaPsim and cytosolic cytochrome c release) associated with procaspase-3 activation, poly(ADP-ribose) polymerase cleavage, and the appearance of the characteristic morphological features of apoptosis. Similar results were obtained using other pharmacological MEK1/2 inhibitors (e.g., PD 98059 and U0126) as well as another leukemic cell line that expresses Bcr-Abl (e.g., LAMA 84). However, synergistic induction of apoptosis by STI571 and PD184352 was not observed in human myeloid leukemia cells that do not express the Bcr-Abl kinase (e.g., HL-60 and U937) nor in normal human peripheral blood mononuclear cells. Synergistic potentiation of STI571-mediated lethality by PD184352 was associated with multiple perturbations in signaling and apoptotic regulatory pathways, including caspase-dependent down-regulation of Bcr-Abl and Bcl-2; caspase-independent down-regulation of Bcl-x(L) and Mcl-1; activation of JNK, p38 MAPK, and p34(cdc2); and diminished phosphorylation of Stat5 and CREB. Significantly, coexposure to PD184352 strikingly increased the lethality of a pharmacologically achievable concentration of STI571 (i.e., 1-2 microM) in resistant K562 cells expressing marked increases in Bcr-Abl protein levels. Together, these findings raise the possibility that treatment of Bcr-Abl-expressing cells with STI571 elicits a cytoprotective MAPK activation response and that interruption of the latter pathway (e.g., by pharmacological MEK1/2 inhibitors) is associated with a highly synergistic induction of mitochondrial damage and apoptosis. They also indicate that in the case of Bcr-Abl-positive cells, simultaneous interruption of two signal transduction pathways may represent an effective antileukemic strategy.

Activating Transcription Factor 1↗

[Evaluation of the combination of psychosocial and pharmacological treatment in schizophrenic patients].

INTRODUCTION: The present treatment of schizophrenia should initially focus on bringing psychotic symptoms under control with the use of antipsychotic medication, but it also should include the psychosocial management of the illness, with the implementation of psychosocial treatment. The purpose of the present study is to describe the results of the comparison of two groups (experimental and control) of schizophrenic out-patients of The National Institute of Psychiatry Ramón de la Fuente in Mexico City. The experimental group received a combination of psychosocial and pharmacological treatment, while the control group received the pharmacological treatment alone. MATERIAL AND METHODS: A quasi-experimental design which included the two groups under study, experimental (n=25) and control group (n=22), was used. Both groups were assessed at the beginning and at the end of a one-year interventions considering variables such as: symptomatology, psychosocial functioning, global functioning, compliance with antipsychotic medication, relapses, rehospitalizations, therapeutic non-compliance, and adherence. RESULTS: Experimental patients, in comparison with control patients, improved their symptomatology, psychosocial functioning and global functioning considerably. They also presented the following: lower relapse frequency - 12% versus 31,8% of the controls as well as low rehospitalizacion rate - 0% versus 13.6% of the control patients, higher antipsychotic medication compliance (90%) when compared with patients under the control condition (80%), a reduced rate of therapeutic non-compliace (19.3%) and a higher degree of adherence (80.7%). On the other hand, control patients remained stabilized in their symptomatology, but did not improved in any of the psychosocial variables. CONCLUSIONS: The results show that the combination of psychosocial and pharmacological therapy is a more effective form of treatment in comparison with the other approach of pharmacotherapy alone. It may be concluded that there is sound evidence that indicates that combined psychosocial and pharmacological therapy combined report beneficial effects for the patients; therefore, it should be considered as an important therapeutic alternative in the treatment of schizophrenic patients.

Adult↗

[Pharmacological treatment of borderline personality disorders. Several options for symptom reduction but nothing for the disorder per se].

There are few guidelines for pharmacological treatment of personality disorders. Some possible explanations for this is discussed: methodological problems, comorbidity and treatment traditions. The few controlled studies published are marred by methodological difficulties such as high frequency of drop outs, lack of compliance, short period of follow-up and differences in diagnostic procedures. The authors propose a dimensional approach focusing on cognitive, affective, anxiety and impulse dysfunction when selecting suitable pharmacological treatment. Global improvement can be seen, when target symptoms are successfully treated. Pharmacological treatment can not replace other treatment strategies such as psychosocial programs. The authors also discuss how pharmacological treatment can be understood in a psychological context. Non-selective MAO-inhibitors are probably underused in Sweden.

Anti-Anxiety Agents↗

Pharmaco-electroencephalography and pharmacokinetic/pharmacodynamic modeling in basic research: focus on human pharmacology.

Pharmacokinetic/pharmacodynamic modeling, together with electroencephalography (EEG), have been successfully applied to obtain in vivo pharmacological information of different drugs acting on the central nervous system (CNS) in humans and of the systems with which the drugs interact. Almost all types of variables used to assess the activity of drugs in the human CNS have already been applied in pharmacokinetic/pharmacodynamic research. However, compared with more traditional approaches to quantify the pharmacodynamics of neuropsychotropic drugs, the EEG method has the advantage of being objective, sensitive, continuous and reproducible. The present review focuses mostly on benzodiazepine pharmacology. A selection of some basic aspects that can be covered using pharmaco-EEG and pharmacokinetic/pharmacodynamic modeling from in vivo studies performed in humans in pharmacological research will be introduced: i) determination of the pharmacological characteristics of a compound; ii) comparison of potencies among drugs; iii) comparison of efficacy among drugs; iv) tolerance development; v) metabolite role; vi) enantiomers; vii) drug-drug interactions; viii) circadian rhythms; ix) factors affecting the observed effect; and x) the gain of physiopathological information about the systems with which drugs interact. Looking at the quantity and quality of the results obtained for the benzodiazepines, pharmacokinetic/pharmacodynamic modeling using EEG measures appears to be an ideal tool, and is potentially useful for other drugs acting on the CNS.

Benzodiazepines↗

Buprenorphine: new pharmacological aspects.

Buprenorphine is an opioid analgesic, derived from thebaine. Buprenorphine was initially classified as a "mixed agonist-antagonist analgesic" or a narcotic antagonist analgesic. The work of Martin et al (1976) on the animal model of the chronic spinal dog substantiated the substance's action as partial agonist at the mu-opioid receptor. These findings were underscored by the substance's general pharmacological profile. Further, buprenorphine was one of the first narcotic analgesics to be assessed for its abuse liability in humans. The lower abuse liability of the drug in humans soon turned it into a widely used therapeutic agent in patients with opioid dependence. Interest in buprenorphine spanning more than 30 years has been attributed to its unique pharmacological characteristics, including moderate intrinsic activity, high affinity to and slow dissociation from mu-opioid receptors. Early pharmacological studies demonstrated buprenorphine's strong binding to opioid receptors, and an inverted U-shaped dose-response curve in rodents. In the rat paw formalin test, although buprenorphine demonstrated a bell-shaped dose-response curve against an acute noxious stimulus, it showed a classic sigmoidal curve in the later phase of the assay. In most preclinical antinociceptive tests, buprenorphine was shown to be fully efficacious, with an antinociceptive potency 25 to 40 times higher than morphine. A ceiling effect for respiratory depression (but not for analgesia) has been demonstrated in humans. Current studies are focusing on norbuprenorphine, an N-dealkylated metabolite of buprenorphine. Norbuprenorphine is a likely contributor to the overall pharmacology of buprenorphine; in the mouse writhing test, norbuprenorphine provides antinociceptive efficacy similar to buprenorphine, with analgesic activity shown to be dose-dependent.

Analgesics, Opioid↗

[Study on pharmacology of ultra-fine particles compound Rehmannia].

OBJECTIVE: To observe pharmacological difference between ultra-fine particles of six ingredient Rehmannia pill and traditional six ingredient Rehmannia pill. METHOD: Pharmacokinetic index was measured by death rate, and pharmacology actions were compared by anti-fatigue, hypoglycemic, clearance rate of charcoal particle, hypoxia resistance and serum hemolysin concentration experiment. RESULT: Dose-effection was significant and pharmacology actions were more than traditional six ingredient Rehmannia pill in six ingredient Rehmannia pill. CONCLUSION: Ultra-fine particles of six ingredient Rehmannia pill are better than traditional six ingredient Rehmannia pill in bioavailability and pharmacology actions, and the weight of pill is reduced while efficacy is enhenced by ultra-fine particles.

Animals↗

General pharmacology of pergolide in animals. 2nd communication: gastrointestinal, renal and miscellaneous studies.

Pergolide mesylate ((8 beta)-8-[(methylthio)methyl]-6-propylergoline monomethanesulfonate, LY 127809, CAS 66104-23-2) is a novel and potent dopamine agonist marketed for treating the symptoms of Parkinson's disease. The potential secondary pharmacological effects of this agent on the gastrointestinal and renal systems, as well as effects on local anesthesia, hemolysis, platelet aggregation, circulating blood glucose, primary antibody production, and the acute inflammatory response were examined. Pergolide exhibited significant pharmacological effects in gastrointestinal, renal and anti-inflammatory tests at high oral doses. Pergolide was essentially inactive in blood hemolysis, platelet aggregation, primary antibody production and local anesthesia testing. In summary, these studies confirm the pharmacological selectivity of pergolide, and indicate a low potential for secondary pharmacological side effects upon the functions tested at clinically relevant doses.

Anesthetics, Local↗

[Prevention of cardiovascular diseases using a combined pharmacological approach: is there any place for a "polypill"?].

In the June 28, 2003 issue of the British Medical Journal, an extensive literature survey based on various large meta-analyses of the efficacy and safety of the reduction of four cardiovascular risk factors (cholesterol, arterial blood pressure, platelet aggregation, homocysteine) leads to the conclusion that a combined pharmacological intervention should reduce ischaemic heart disease events by 88% and strokes by 80% in at risk individuals. Therefore, a new paradigm is proposed for the prevention of cardiovascular diseases. This new strategy would consist in the systematic prescription to people with a history of heart attack or stroke, those with any form of obliterative atherosclerotic vascular disease or diabetes, and everyone aged 55 and older of a fixed combination of 6 pharmacological agents independently of initial risk factor profile.... Such pharmacological formulation, called "polypill", should contain a statin, three blood pressure lowering drugs (each at half standard dose), aspirin (75 mg/day) and folic acid (0.8 mg/day). We discuss the pros and cons of this new paradigm. However, the efficacy of such "polypill" remains to be demonstrated in a large controlled clinical trial as well as its superiority as compared to a classical approach of cardiovascular prevention based upon the individual optimal correction of each risk factor thanks a dose titration of each pharmacological compound.

Antihypertensive Agents↗